The Therapeutic Pipeline for Pseudomonas aeruginosa Infections
The Therapeutic Pipeline for Pseudomonas aeruginosa Infections
复制标题
DOI：
10.1021/acsinfecdis.8b00112
复制
发表时间：
2018-07-01
影响因子：
5.3
通讯作者：
Burrows, Lori L.
中科院分区：
文献类型：
--
作者：
Burrows, Lori L.
铜绿假单胞菌是一种革兰氏阴性机会性病原体，由于具有高度的内在和获得性抗生素耐药性，被世界卫生组织指定为开发新疗法的关键优先事项。其他挑战包括它的多功能性（它可以在环境中持续存在，大多数菌株能够在受损的宿主中引起疾病），限制药物渗透的强大外排机制，以及形成抗菌素耐受性生物膜的倾向。正在开发的预防或治疗铜绿假单胞菌感染的新疗法包括疫苗、生物制剂（如抗菌肽和治疗性抗体）、毒力抑制剂、具有新靶点的抗菌剂、抗体-药物偶联物、耐药抑制剂-抗生素或抗生素-增强剂组合、噬菌体或噬菌体衍生的溶酶。
Pseudomonas aeruginosa is a Gram-negative opportunistic pathogen, designated by the World Health Organization as a critical priority for development of new therapeutics due to high levels of intrinsic and acquired antibiotic resistance. Other challenges include its versatility (it can persist in the environment and most strains are capable of causing disease in compromised hosts), robust efflux mechanisms that limit drug penetration, and the propensity to form antimicrobial-tolerant biofilms. Novel therapeutics in development to prevent or treat P. aeruginosa infections include vaccines, biologics such as antimicrobial peptides and therapeutic antibodies, virulence inhibitors, antimicrobials with novel targets, antibody-drug conjugates, resistance inhibitor-antibiotic or antibiotic-potentiator combinations, and bacteriophages or phage-derived lysins.